in the hope of preparing a regulatory filing for the EAPP test in 2025. Roche’s Genentech division reported disappointing top-line results from its highly-anticipated phase 3 trial of anti ...
Genentech, which is a member of the Roche Group, has also submitted Marketing Authorisation Applications to other regulatory authorities around the world, including the European Medicines Agency ...
Hosted on MSN2mon
Genentech announces FDA acceptance of Columvi combination sBLAGenentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application, or sBLA, for Columvi in combination with gemcitabine and ...
Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study investigating Itovebi in combination with palbociclib and ...
Genentech raised nearly $2 billion during its second initial public offering (IPO) on July 20 when Roche Holding refloated part of the company after acquiring all outstanding shares in June ...
Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus nephritis was published in the New England Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback